Core Viewpoint - The company has announced a delay in the investment projects funded by raised capital, extending the expected completion dates for two key projects to December 31, 2026 [1][2]. Group 1: Project Delay Announcement - The board of directors approved the extension of the "Intelligent Upgrade of High-end Chemical Equipment Production Line" and "Technical Research Center (Huitong Research Institute)" projects [1][2]. - The delay is attributed to fluctuations in the macroeconomic environment and changes in downstream market demand, leading to an optimization of the investment pace for the projects [2][3]. Group 2: Financial Details of Investment Projects - The total amount of raised funds for the projects is 353.72 million yuan, with 252.30 million yuan allocated for the Technical Research Center project [2][3]. - As of November 30, 2025, the cumulative investment in the Technical Research Center project reached 109.07 million yuan, representing 43.23% of the planned investment [2][3]. Group 3: Impact of the Delay - The delay does not involve changes to the project implementation entities, methods, content, purposes, or investment scales, and is not expected to materially affect the implementation of the projects [2][3]. - The decision to extend the project timeline is considered prudent and aligns with the company's long-term development strategy, aiming to enhance the projects' benefits [2][3].

Core Viewpoint - Huitong Technology announced the extension of the completion date for its IPO fundraising projects to December 31, 2026, without changing the purpose, scale, or implementation entity of the projects [1]. Group 1: Project Details - The projects affected by the extension are the "Intelligent Upgrade and Technical Transformation Project for High-end Chemical Equipment Production Line" and the "Technical Research Center (Huitong Research Institute) Project" [1]. - A total of 109.075 million yuan has been invested in these projects to date [1]. Group 2: Implications of the Announcement - The extension is solely a schedule adjustment and does not require submission to the shareholders' meeting [1].